Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults

Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint stockholders to approve the transaction to take place on May 28, 2025

Read more at globenewswire.com